Document Detail


Effects of bevacizumab on apoptosis, Na+ -K+ -adenosine triphosphatase and zonula occludens 1 expression on cultured corneal endothelial cells.
MedLine Citation:
PMID:  20173357     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: This laboratory study was undertaken to investigate the influence of bevacizumab on apoptosis, Na(+)-K(+)-adenosine triphosphatase (Na(+)-K(+)-ATPase) and zonula occludens 1 (ZO-1) expression on cultured human corneal endothelial cells (HCECs).
METHODS: Annexin V binding combined with propidium iodide (PI) costaining was used to distinguish viable, early and late apoptotic cells. Immunolocalization of ZO-1 and Na(+)-K(+)-ATPase was performed to analyze intercellular cell integrity after exposure to 5.0 mg/ml bevacizumab for 24 h.
RESULTS: No significant induction of apoptosis or necrosis was seen in HCECs after exposure to 5.0 mg/ml bevacizumab (p = 0.689, p = 0.516, respectively). The mean number of annexin-V-FITC- and PI-positive cells did not change significantly. Additionally, no significant changes in expression were detectable, neither for ZO-1 nor for Na(+)-K(+)-ATPase in comparison with the control. For ZO-1, 70.0% of the cells stained intensely, 24.7% stained moderately, and 5.3% stained weakly in the control group. After exposure to 5.0 mg bevacizumab, only minor changes were observable: 68.8% stained intensely, 25.4% moderately and 5.8% weakly (p = 0.524). For Na(+)-K(+)-ATPase, 19.3% of the cells stained intensely, 59.4% moderately, and 21.3% weakly in the control group. After exposure to 5.0 mg bevacizumab, again only minor changes were observable in the expression pattern: 18.2% stained intensely, 60.3% moderately and 21.5% weakly. The changes were not significant compared with the control (p = 0.492).
CONCLUSIONS: Bevacizumab, at concentrations used clinically, did not induce apoptosis or necrosis in HCECs in vitro. Additionally, no alteration of ZO-1 or Na(+)/K(+)-ATPase expression was detected after exposure to 5.0 mg/ml bevacizumab for 24 h.
Authors:
Efdal Yoeruek; Olcay Tatar; Martin S Spitzer; Oguzhan Saygili; Tilo Biedermann; Karl U Bartz-Schmidt; Sebastian Thaler; Peter Szurman
Related Documents :
8382207 - K+ fluxes mediated by na(+)-k(+)-cl- cotransport and na(+)-k(+)-atpase pumps in renal t...
15121097 - Cell shrinkage activates na+/h+ exchange in dog red cells by relieving inhibition of ex...
8577837 - The sodium pump in the evolution of animal cells.
2928347 - Steroid hormones: modulators of na+ absorption and cl- secretion in cultured tracheal e...
6340477 - Female germ cell loss from radiation and chemical exposures.
17947527 - Endogenous low-level expression of the coxsackievirus and adenovirus receptor enables c...
Publication Detail:
Type:  Journal Article     Date:  2010-02-19
Journal Detail:
Title:  Ophthalmic research     Volume:  44     ISSN:  1423-0259     ISO Abbreviation:  Ophthalmic Res.     Publication Date:  2010  
Date Detail:
Created Date:  2010-06-10     Completed Date:  2010-10-21     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  0267442     Medline TA:  Ophthalmic Res     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  43-9     Citation Subset:  IM    
Copyright Information:
(c) 2010 S. Karger AG, Basel.
Affiliation:
Department of Ophthalmology, Eberhard-Karl University, Tuebingen, Germany. Efdal.Yoeruek @ med.uni-tuebingen.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiogenesis Inhibitors / pharmacology*
Annexin A5 / metabolism
Antibodies, Monoclonal / pharmacology*
Antibodies, Monoclonal, Humanized
Apoptosis / drug effects*
Cells, Cultured
Endothelium, Corneal / drug effects*,  metabolism,  pathology
Humans
Immunoenzyme Techniques
Membrane Proteins / metabolism*
Middle Aged
Phosphoproteins / metabolism*
Sodium-Potassium-Exchanging ATPase / metabolism*
Vascular Endothelial Growth Factor A / antagonists & inhibitors*
Zonula Occludens-1 Protein
Chemical
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Annexin A5; 0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Membrane Proteins; 0/Phosphoproteins; 0/TJP1 protein, human; 0/VEGFA protein, human; 0/Vascular Endothelial Growth Factor A; 0/Zonula Occludens-1 Protein; 2S9ZZM9Q9V/bevacizumab; EC 3.6.3.9/Sodium-Potassium-Exchanging ATPase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Role of the Left DLPFC in Endogenous Task Preparation: Experimental Repetitive Transcranial Magnetic...
Next Document:  Transoral Robotic Tongue Base Resection in Obstructive Sleep Apnoea-Hypopnoea Syndrome: A Preliminar...